Psychedelic Research & Therapy Development (Dr. M. Scheidegger)

Our research group is dedicated to advancing the understanding of psychedelic medicines and their therapeutic potential in mental health. By investigating their transdiagnostic mechanisms of action, we aim to uncover how psychedelics enhance neurobehavioral plasticity, facilitate therapeutic experiences, and support psychotherapeutic processes.

We integrate neuroscience, clinical research, and psychotherapy development to study compounds such as ayahuasca-analogue DMT formulations, 5-MeO-DMT, psilocybin, and ketamine. Our mission is to bridge early-phase clinical research and drug development with psychotherapy innovation, translating basic science into safe, effective, and scalable interventions that redefine psychedelic treatment paradigms in mental health care.